Literature DB >> 10590083

The tyrosine kinase abl-related gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts.

G Cazzaniga1, S Tosi, A Aloisi, G Giudici, M Daniotti, P Pioltelli, L Kearney, A Biondi.   

Abstract

The Ets variant gene 6 (ETV6/TEL) gene is rearranged in the majority of patients with 12p13 translocations fused to a number of different partners. We present here a case of acute myeloid leukemia M4 with eosinophilia (AML-M4Eo) positive for the CBFb/MYH11 rearrangement and carrying a t(1;12)(q25;p13) that involves the ETV6 gene at 12p13. By 3'rapid amplification of cDNA ends-polymerase chain reaction (3'RACE-PCR), a novel fusion transcript was identified between the ETV6 and the Abelson-related gene (ARG) at 1q25, resulting in a chimeric protein consisting of the HLH oligomerization domain of ETV6 and the SH2, SH3, and protein tyrosine kinase (PTK) domains of ARG. The reciprocal transcript ARG-ETV6 was also detected in the patient RNA by reverse transcriptase-polymerase chain reaction (RT-PCR), although at a lower expression level. The ARG gene encodes for a nonreceptor tyrosine kinase characterized by high homology with c-Abl in the TK, SH2, and SH3 domains. This is the first report on ARG involvement in a human malignancy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10590083

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity.

Authors:  A Buijs; L van Rompaey; A C Molijn; J N Davis; A C Vertegaal; M D Potter; C Adams; S van Baal; E C Zwarthoff; M F Roussel; G C Grosveld
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Two distinct phosphorylation pathways have additive effects on Abl family kinase activation.

Authors:  Keith Q Tanis; Darren Veach; Henry S Duewel; William G Bornmann; Anthony J Koleske
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

3.  Array comparative genomic hybridization detects chromosomal abnormalities in hematological cancers that are not detected by conventional cytogenetics.

Authors:  Lina Shao; Sung-Hae L Kang; Jian Li; Patricia Hixson; Jesalyn Taylor; Svetlana A Yatsenko; Chad A Shaw; Aleksandar Milosavljevic; Chung-Che Chang; Sau Wai Cheung; Ankita Patel
Journal:  J Mol Diagn       Date:  2010-08-19       Impact factor: 5.568

4.  Structure of the ABL2/ARG kinase in complex with dasatinib.

Authors:  Byung Hak Ha; Mark Adam Simpson; Anthony J Koleske; Titus J Boggon
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-03-20       Impact factor: 1.056

Review 5.  Abl tyrosine kinases in T-cell signaling.

Authors:  Jing Jin Gu; Jae Ryun Ryu; Ann Marie Pendergast
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

6.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

7.  Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.

Authors:  Michael H Tomasson; Zhifu Xiang; Richard Walgren; Yu Zhao; Yumi Kasai; Tracie Miner; Rhonda E Ries; Olga Lubman; Daved H Fremont; Michael D McLellan; Jacqueline E Payton; Peter Westervelt; John F DiPersio; Daniel C Link; Matthew J Walter; Timothy A Graubert; Mark Watson; Jack Baty; Sharon Heath; William D Shannon; Rakesh Nagarajan; Clara D Bloomfield; Elaine R Mardis; Richard K Wilson; Timothy J Ley
Journal:  Blood       Date:  2008-02-12       Impact factor: 22.113

8.  Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.

Authors:  Cristina E Tognon; Cameron D Mackereth; Aruna M Somasiri; Lawrence P McIntosh; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

9.  The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors.

Authors:  Keiko Okuda; Yuko Sato; Yoshiaki Sonoda; James D Griffin
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

Review 10.  Translocations in epithelial cancers.

Authors:  J Chad Brenner; Arul M Chinnaiyan
Journal:  Biochim Biophys Acta       Date:  2009-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.